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0939-4753/ª 2019 The Author(s). This is an opAbstract Aims: This joint document of the Italian Diabetes Society and the Italian Society of
Nephrology reviews the natural history of diabetic kidney disease (DKD) in the light of the recent
epidemiological literature and provides updated recommendations on anti-hyperglycemic treat-
ment with non-insulin agents.
Data synthesis: Recent epidemiological studies have disclosed a wide heterogeneity of DKD. In
addition to the classical albuminuric phenotype, two new albuminuria-independent phenotypes
have emerged, i.e., “nonalbuminuric renal impairment” and “progressive renal decline”, suggest-
ing that DKD progression toward end-stage kidney disease (ESKD) may occur through two
distinct pathways, albuminuric and nonalbuminuric. Several biomarkers have been associated
with decline of estimated glomerular filtration rate (eGFR) independent of albuminuria and
other clinical variables, thus possibly improving ESKD prediction. However, the pathogenesis
and anatomical correlates of these phenotypes are still unclear. Also the management of hyper-
glycemia in patients with type 2 diabetes and impaired renal function has profoundly changed
during the last two decades. New anti-hyperglycemic drugs, which do not cause hypoglycemia
and weight gain and, in some cases, seem to provide cardiorenal protection, have become avail-
able for treatment of these individuals. In addition, the lowest eGFR safety thresholds for some of
the old agents, particularly metformin and insulin secretagogues, have been reconsidered.
Conclusions: The heterogeneity in the clinical presentation and course of DKD has important im-
plications for the diagnosis, prognosis, and possibly treatment of this complication. Thernals Journal of Nephrology and Nutrition Metabolism and Cardiovascular Disease. https://doi.org/10.1007/
f Clinical and Molecular Medicine, “La Sapienza” University, Rome, Italy.
iroma1.it (G. Pugliese).
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Diabetic nephropathy is a major long-term complication
affecting approximately 30% of patients with type 1
diabetes (T1D) and 40% of those with type 2 diabetes
(T2D) [1]. Nowadays, it represents the leading cause of
end-stage kidney disease (ESKD) worldwide, accounting
for approximately 40% of new patients requiring renal
replacement therapy [2]. Recently, epidemiological sur-
veys have highlighted the unique heterogeneity of the
natural history of this complication, thus prompting the
use of “diabetic kidney disease” (DKD) to encompass all
types of renal injury occurring in diabetic individuals [3].
In particular, in addition to the classical albuminuric
phenotype, two new phenotypes have emerged, i.e.,
“nonalbuminuric renal impairment” and “progressive
renal decline”, which suggest that DKD progression to-
ward ESKD in both T1D and T2D may occur through two
distinct pathways heralded by a progressive increase in
albuminuria and decline in glomerular filtration rate
(GFR), respectively [4]. Furthermore, during the last two
decades, the management of hyperglycemia in T2D pa-
tients with impaired renal function has profoundly
changed, as several new anti-hyperglycemic drugs have
become available for treatment of these individuals and
the lowest GFR safety thresholds for some of the old
agents have been reconsidered [5]. This joint document
of the Italian Diabetes Society (SID) and the Italian So-
ciety of Nephrology (SIN) extensively reviews the natural
history of DKD in the light of the recent epidemiological
literature, though a systematic review of the literature
was not made. In addition, it provides updated recom-
mendations on anti-hyperglycemic treatment with non-
insulin agents in patients with T2D and impaired renal
function.
Natural history of DKD
In the traditional, five-stage natural history of diabetic
nephropathy, microalbuminuria represents the first
abnormality occurring in individuals suffering from
this complication. It later progresses to macro-
albuminuria, which in turn precedes GFR decline,
usually in parallel with development and progression
of retinopathy [6]. For this reason, the screening and
diagnosis of diabetic nephropathy have been tradi-
tionally based on the assessment of albuminuria [7].
Furthermore, albuminuria has long been considered as
the main prognostic factor for both progression to
ESKD and morbidity and mortality from cardiovascular
disease (CVD) [8]. Finally, clinical trials with renopro-
tective agents, such as the blockers of the renin-
angiotensin system (RAS), have generally tested theet al., Diabetic kidney disease: N
lian Society of Nephrology on “T
trition, Metabolism & Cardiovasefficacy of these drugs in halting progression and/or
favoring regression of albuminuria from one category
to another [9], based on the assumption that targeting
albuminuria in diabetic individuals results in better
renal and CVD outcomes [10].
This albuminuria-centric model of the natural history of
diabetic nephropathy has been questioned by a number of
epidemiological observations accumulated during the last
decades on the incidence and prevalence of DKD and its
main manifestations, i.e., increased albuminuria and
reduced GFR, usually estimated using different formulas
(eGFR).
These data indicate that the overall burden of DKD has
not decreased during this period. Serial cross-sectional
analyses of the National Health and Nutrition Examination
Survey (NHANES) data from 1988 through 2014 have
shown that, among US adults with diabetes, prevalence of
DKD has remained stable during this period [11]. In
contrast, serial cross-sectional studies conducted in a
Japanese diabetic population have demonstrated that
prevalence of DKD has increased from 18.5% in 1996 to
25.6% in 2014 [12]. Finally, data from the National Health
Interview Survey, the National Hospital Discharge Survey,
the US Renal Data System, and the US National Vital Sta-
tistics System have indicated that, among the major dia-
betic complications, ESKD has shown the smallest decline
between 1990 and 2010 among US adults with diabetes,
likely due to the marked decrease in the incidence of acute
myocardial infarction and stroke, which may have favored
DKD progression toward its later stages by reducing mor-
tality from CVD [13].
Conversely, impressive diverging changes have been
reported in the prevalence of albuminuria and reduced
eGFR. The NHANES data have shown that, from 1988 to
2014, the prevalence of albuminuria has declined by 24%
(adjusted prevalence ratio 2009e2014 vs 1988e1994, 0.76
[95% confidence interval, 0.65e0.89], P < 0.001), that of
macroalbuminuria has remained rather stable (0.82
[0.59e1.14], P Z 0.22), and that of eGFR <60 ml/min/
1.73 m2 and especially <30 ml/min/1.73 m2 has dramati-
cally increased (1.61 [1.33e1.95], P < 0.001, and 2.86
[1.38e5.9]), P < 0.004, respectively) [11]. Similar secular
trends in the prevalence of albuminuria and reduced eGFR
have been reported in the Japanese diabetic population
from 1996 through 2014 [12].
These opposite temporal trends in the prevalence of
albuminuria and reduced eGFR reflect the fact that
remission/regression of microalbuminuria (and even
macroalbuminuria) to normoalbuminuria is an increas-
ingly common feature that far outweighs progression to
proteinuria in both T1D [14e16] and T2D [17e19], whereas
eGFR loss, once initiated, continue to progress inevitably
to ESKD, albeit at widely variable rates. The increasingew clinical and therapeutic issues. Joint position statement of the
he natural history of diabetic kidney disease and treatment of
cular Diseases, https://doi.org/10.1016/j.numecd.2019.07.017
New issues in DKD 3divergence between albuminuria and reduced eGFR chal-
lenges the classical view that albuminuria invariably pre-
cedes and sustains eGFR loss, suggesting that both
initiation and progression of renal function decline may
occur also independently of the development of albu-
minuria and its subsequent course. This concept is sup-
ported by the emergence of two new phenotypes, i.e.,
nonalbuminuric renal impairment and progressive renal
decline.Box 1. During the last decades, prevalence of DKD
has not decreased and incidence of ESKD has
decreased only slightly, with major changes in the
two main DKD manifestations, i.e., albuminuria, the
prevalence of which has decreased (with macro-
albuminuria remaining stable), and reduced eGFR,
the prevalence of which has increased (especially
2for eGFR <30 ml/min/1.73 m ).Nonalbuminuric renal impairment and progressive renal
decline
Two early studies reported that reduction of creatinine
clearance may occur in patients with both T1D and T2D
who remain normoalbuminuric [20,21]. These observa-
tions have been confirmed in the last decades, during
which the prevalence of the nonalbuminiric phenotype
has increased among individuals with T2D (Table 1) and,
though to a lower extent, also with T1D (Table 2).
A cross-sectional analysis of US adults with diabetes
from the NHANES 1988e1994 showed that 35.1% of sub-
jects with an eGFR <60 ml/min/1.73 m2, as calculated
using the Modification of Diet in Renal Disease (MDRD)
formula, were normoalbuminuric, and that albuminuria
and retinopathy were both absent in 29.8% of patients with
reduced eGFR [22]. Subsequent cross-sectional analyses of
the NHANES data showed higher adjusted prevalence rates
(w50%) for the nonalbuminuric phenotype among in-
dividuals with reduced eGFR, as calculated using the
Chronic Kidney Disease Epidemiology Collaboration (CKD-
EPI) equation, i.e., 45.8%, in the years 1988e1994 [23],
47.7%, in the years 1999e2012 [24], 51.8%, in the years
2001e2008 [25], and 48.1%, in the years 2005e2008 [11].
These data are consistent with the decreasing prevalence
of albuminuria and the increasing prevalence of reduced
eGFR reported among US [11] and Japanese [12] adults
with diabetes.
Similar findings have emerged from cross-sectional
studies in cohorts of T2D patients from several coun-
tries. McIsaac et al. reported that, among 301 patients
with T2D attending an outpatient clinic in Australia in
the years 1990e2001, 39.4% of those with an GFR
<60 ml/min/1.73 m2, as measured by an isotopic
method, were normoalbuminuric [26]. All the surveys
conducted in the subsequent years reported a rising
prevalence (increasing approximately from 40 to 70%) ofPlease cite this article as: Pugliese G et al., Diabetic kidney disease: N
Italian Diabetes Society and the Italian Society of Nephrology on “T
hyperglycemia in patients with..., Nutrition, Metabolism & Cardiovascthe nonalbuminuric phenotype among T2D patients
with reduced eGFR, with differences among studies
depending also on the geographic area and the formula
used for eGFR calculation. In detail, prevalence was:
40.1% in the Developing Education on Microalbuminuria
for Awareness of renal and cardiovascular risk in Dia-
betes (DEMAND) Study (multinational, MDRD, 2003)
[27,28]; 51.8% in the Japan Diabetes Clinical Data Man-
agement (JDDM) Study (Japan, MDRD, 2004e2005) [29];
54.2% in the National Evaluation of the Frequency of
Renal Impairment cO-existing with NIDDM (NEFRON)
(Australia, MDRD, 2005) [30,31]; 56.6% in the Renal
Insufficiency And Cardiovascular Events (RIACE) Italian
Multicenter Study (Italy, MDRD, 2006e2008) [32]; 61.9%
in an analysis of the Swedish National Diabetes Register
(Sweden, MDRD, 2007) [33]; 63.7% in the UK National
Diabetes Audit (UK, CKD-EPI, 2007e2008) [34]; 48.2% in
the AMD-Annals Initiative (Italy, CKD-EPI, 2009) [35];
69.9% in a Chinese cohort (China, CKD-EPI, 2008e2009)
[36]; 69.4% in the Prevalence of ease in Patients with
Type 2 Diabetes (PERCEDIME2) Study (Spain, MDRD,
2011) [37] and 68.3% in the Diabetes-Patienten-
Verlaufsdokumentation (DPV) and DIabetes
Versorgungs-Evaluation (DIVE) registries (Germany,
MDRD, 2010e2017) [38]. Lower prevalence rates were
reported in two epidemiological surveys from Korea
(23.7%) [39] and US (the Chronic Renal Insufficiency
Cohort [CRIC] Study, 28.4%) [40], but patients whose
albuminuria status was possibly related to RAS blocker
therapy were excluded from these analyses.
A high prevalence of the nonalbuminuric phenotype
(ranging approximately from 45% to 70%) was also detec-
ted in T2D patients enrolled in multicenter multinational
interventional studies, in which however values were
affected by the different entry criteria. In detail, prevalence
was: 59.1% in the Fenofibrate Intervention and Event
Lowering in Diabetes (FIELD) Study (MDRD, 1998e2000)
[41]; 61.6% in the Action in Diabetes and Vascular disease:
preterAx and diamicroN-MR Controlled Evaluation
(ADVANCE) Study (MDRD, 2001e2003) [42]; 68.2% in the
Ongoing Telmisartan Alone and in Combination with
Ramipril Global Endpoint Trial (ONTARGET) and Telmi-
sartan Randomised AssessmeNt Study in ACE iNtolerant
subjects with cardiovascular Disease (TRASCEND) Study
(MDRD, 2001e2004) [43]; and 46.8% in the Avoiding Car-
diovascular Events in Combination Therapy in Patients
Living with Systolic Hypertension (ACCOMPLISH) Study
(MDRD, 2003e2005) [44].
Altogether, these data support the concept that preva-
lence of nonalbuminuric renal impairment in T2D has
increased during the last decades and that it has now
become the prevailing phenotype among patients with
reduced eGFR. Currently, it can be estimated that, among
T2D individuals, 50e65% have no DKD, 20e30% have
albuminuria alone (i.e., albuminuric DKD with preserved
eGFR), and 15e25% have reduced eGFR, the majority of
them (8e16%) with normoalbuminuria (i.e., non-
albuminuric DKD or reduced eGFR alone) and the
remaining with micro or macroalbuminuria (i.e.,ew clinical and therapeutic issues. Joint position statement of the
he natural history of diabetic kidney disease and treatment of
ular Diseases, https://doi.org/10.1016/j.numecd.2019.07.017
Table 1 Distribution of DKD phenotypes in individuals with T2D.
Study Country Years GFR method N T2D, % Alb eGFR, % Albþ eGFR, % eGFRþ, %
All, % Albþ, % Alb.,
%
Alb, %
of all
eGFRþ
Alb-/Ret-,
% of all
eGFRþ
Cross-sectional serial (NHANES)
Kramer HJ et al. JAMA.
2003; 24:3273e3277
(NHANES 1988
e1994)
US 1988e1994 MDRD 1197 100 54.0 31.7 14.3 9.3 5.0 35.1 29.8
Afkarian M et al. J Am
Soc Nephrol. 2013;
24:302e308
(NHANES 1988
e1994)
US 1988e1994 CKD-EPI 1430 100 54.0 27.1 19.0 10.3 8.7 45.8 e
Bailey RA et al. BMC
Research Notes.
2014; 7:415
(NHANES 1999
e2012)
US 1999e2012 CKD-EPI
(þMDRD)
2915 100 51.0 24.0 25.0 13.1 11.9 47.7 e
1466
65 years
100 38.7 20.4 40.8 21.3 19.5 47.7 e
Mottl AK et al. J
Diabetes
Complications. 2013;
27:123e127
(NHANES 2001
e2008)
US 2001e2008 CKD-EPI 2798 100 56.5 23.0 20.5 9.9 10.6 51.8 e
Cross-sectional (observational)
MacIsaac RJ et al.
Diabetes Care. 2004;
7:195e200
Australia 1990e2001 isotopic 301 100 38.2 25.6 36.3 21.9 14.3 39.4 29.3
Dwyer JP et al.
Cardiorenal Med.
2012; 2:1e10;
Parving HH et al.
Kidney Int. 2006;
69:2057e2063
(DEMAND Global)
33 countries from
Europe, Asia, Africa,
Oceania, North &
Central-South America
2003 MDRD 11,573 100 43 34 23 13 9 40.1 e
Yokoyama H et al.
Nephrol Dial
Transplant. 2009;
24:1212e1219
(JDDM)
Japan 2004e2005 MDRD Jap 3297 100 61.8 22.9 15.3 7.4 7.9 51.8 39.9
Thomas MC et al. Med J
Aust. 2006; 185:140
e144; Thomas MC
et al. Diabetes Care.
2009; 32:1497e1502
(NEFRON)
Australia 2005 MDRD 3893 100 52.9 24.2 22.9 10.5 12.4 54.1 e
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Penno G et al. J
Hypertens. 2011;
29:1802e1809
(RIACE)
Italy 2006e2008 MDRD
(þCDD-EPI)
15,773 100 62.5 18.7 18.8 8.2 10.6 56.6 43.2
Afghahi H et al. J
Diabetes
Complications. 2013;
27: 229e234
(Swedish National
Diabetes Register)
Sweden 2007 MDRD
(þCockcroft-
Gault)
81,315 100 63.5 16.4 20.0 7.6 12.4 61.9 49.6
Hill CJ et al. Diabet Med
2014; 31:448e454
(UK National
Diabetes Audit)
UK 2007e2008 CKD-EPI 800,439 100 57.7 17.7 24.5 8.9 15.6 63.7 e
Koye DN et al. Am J
Kidney Dis. 2018; 72:
653e661 (CRIC)
US 2003e2008 CKD-EPI 1,908a (eGFR 21
e44 yrs > 20
<70,
45e64 yrs < 60,
65e74 yrs < 50)
100 e e 100.0 71.6 28.4 28.4
De Cosmo S et al.
Nephrol Dial
Transplant 2014;
29:657e662 (AMD
Annals)
Italy 2009 CKD-EPI 120,903 100 52.6 23.8 23.5 12.2 11.3 48.2 39.3
Gao B et al. J Diabetes
Complications. 2019;
33:39e45
China 2008e2009 CKD-EPI 8811 100 67.2 17.5 15.3 4.6 10.7 69.9 e
Lee UW et al.
Endocrinol Metab.
2016; 31: 577-585
Korea 2011e2013 MDRD
(þCKD-EPI)
1,067a 100 30.1 31.1 38.8 29.6 9.2 23.7 17.1
Rodriguez-Poncelas A
et al. BMC Nephrol.
2013; 14:46
(PERCEDIME2)
Spain 2011 MDRD 1145 100 62.1 9.9 18.0 12.5 5.5 69.4 e
Bramlage P et al.
Cardiovasc Diabetol.
2019; 18:33 (DPV/
DIVE Registry)
Germany 2010e2017 MDRD 240,510 100 45.1 15.8 39.3 12.4 26.9 68.3 e
Cross-sectional (intervention)
Drury Pl et al.
Diabetologia. 2011;
54:32e43 (FIELD)
Australia, New Zealand,
Finland
1998e2000 MDRD 9795 100 71.2 23.4 5.3 2.2 3.1 59.1 e
Ninomiya T et al. J Am
Soc Nephrol, 2009;
20:1813e1821
(ADVANCE)
20 countries from
Europe, Asia, Oceania,
North America
2001e2003 MDRD 10,640 100 57.5 23.3 19.2 7.3 11.8 61.6 e
Tobe SW et al.
Circulation. 2011;
123:1098e1107
(ONTARGET
&TRASCEND)
40 countries from
Europe, Asia, Oceania,
North America
2001e2004 MDRD 23,422 37.5 61.9 14.1 24.0 7.6 16.4 68.2 e
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albuminuria and reduced eGFR) (Table 1).
A high prevalence of the nonalbuminuric phenotype
has been observed also in individuals with T1D. A cross-
sectional analysis of the Finnish Diabetic Nephropathy
(FinnDiane) Study cohort detected that 15.5% of the 502
T1D patients with reduced eGFR were normoalbuminuric
(Finland, CKD-EPI, 1998e2005) [45]. However, more recent
cross-sectional studies from Italy and UK reported a much
higher prevalence (approximately 50e60%) of the non-
albuminuric phenotype among T1D patients with reduced
eGFR, i.e., 58.6% in a cohort study from Tuscany (Italy,
MDRD, 2001e2009) [46]; 48.9% and 51.5% in the AMD-
Annals Initiative (Italy, CKD-EPI, 2004e2011) [47,48]; and
54.4% in the UK National Diabetes Audit (UK, CKD-EPI,
2007e2008) [34]. These data seem to indicate that prev-
alence of nonalbuminuric renal impairment is increasing
also in T1D and that, nowadays, it is at least as frequent as
the albuminuric phenotype among T1D individuals with
impaired renal function.
Longitudinal analyses of patients with T2D from the
United Kingdom Prospective Diabetes Study (UKPDS) and
of patients with T1D from the Diabetes Control and
Complications Trial (DCCT)/Epidemiology of Diabetes
Interventions and Complications (EDIC) provided infor-
mation on the course of albuminuria and reduced eGFR
in these individuals. In the UKPDS, of the 1132 in-
dividuals (28.3% of the overall cohort) who developed
reduced eGFR over a 15-year follow-up, 67.1% were nor-
moalbuminuric and 50.8% remained in this category,
whereas 16.3% became microalbuminuric thereafter (UK,
Crockcroft-Gault) [49]. Likewise, in the DCCT/EDIC Study,
of the 89 individuals (6.2% of the overall cohort) devel-
oping reduced eGFR during a 19-year follow-up, 23.6%
were normoalbuminuric (North America, MDRD) [50].
These data indicate not only that eGFR may decline prior
to the increase of albuminuria, but also that reduced
eGFR may remain the sole renal abnormality in a sub-
stantial proportion of patients with DKD or become
associated with albuminuria only later. Thus, albumin-
uric DKD with reduced eGFR represents a heterogeneous
DKD phenotype, including individuals progressing along
the classical pathway characterized by eGFR decline only
after the development and progression of micro-
albuminuria and those presenting initially with non-
albuminuric renal impairment and developing
albuminuria only at a later stage.
Finally, Krolewski et al. identified the phenotype of
progressive renal decline by analyzing the slope of eGFR in
diabetic patients enrolled in the Joslin Kidney Studies [51].
This phenotype was observed in 19% of T1D and 28% of
T2D individuals [52] and now accounts for the majority of
ESKD cases in T1D [53]. It is characterized by eGFR loss
which occurs early (or late) in the natural history of dia-
betic nephropathy, while patients have normal renal
function, and progresses unidirectionally to ESKD at a
variable rate, from slow to very fast [52]. Progression was
shown to be mainly linear, with only a small percentage of
patients exhibiting non-linear decline with acceleration orew clinical and therapeutic issues. Joint position statement of the
he natural history of diabetic kidney disease and treatment of
cular Diseases, https://doi.org/10.1016/j.numecd.2019.07.017
Table 2 Distribution of DKD phenotypes in individuals with T1D.
Study Country Years GFR method N T1D, % Alb eGFR, % Albþ eGFR, % eGFRþ, %
All,
%
Albþ,
%
Alb.,
%
Alb, % of
all eGFRþ
Alb/Ret, %
of all eGFRþ
Cross-sectional
Thorn LM et al. Diabetes
Care. 2015; 38:2128
e2133 (FinnDiane)
Finland 1998e2005 CKD-EPI 3809 100 67.4 19.4 13.1 11.1 2.0 15.5 e
Penno G et al.
Diabetologia. 2017;
60:1102e1113
Italy 2001e2009 MDRD 777 100 89.4 6.8 3.7 1.5 2.2 58.6 11.1
Pacilli A et al. Diabetes
Metab Res Rev. 2017;
33 (4) (AMD-Annals)
Italy 2004e2011 CKD-EPI 20,464 100 76.5 15.4 8.0 4.1 3.9 48.9 e
Lamacchia O et al.
Diabetol Metab
Syndr. 2018; 10:60
(AMD-Annals)
Italy 2004e2011 CKD-EPI 1395
(eGFR 60 ml/
min/1.73 m2)
100 e e 100.0 48.5 51.5 51.5 36.6
Hill CJ et al. Diabet Med.
2014; 31:448e454
(UK National
Diabetes Audit)
UK 2007e2008 CKD-EPI 68,177 100 67.6 18.4 14.0 6.4 7.6 54.4 e
Longitudinal
Molitch ME et al.
Diabetes Care. 2010;
33:1536e1543
(DCCT/EDIC)
North
America
1983e1989 MDRD 1439
(mean
follow-up
of 19 yrs)
100 46.9 46.9 6.2 4.7 1.5 23.6 e
AlbþZ micro or macroalbuminuria; AlbZ normoalbuminuria; eGFRþZ <60 ml/min/1.73 m2; eGFRZ 60 ml/min/1.73 m2; RetZ no retinopathy; FinnDianeZ Finnish Diabetic Nephropathy
Study; DCCT/EDIC Z Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications.
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8 G. Pugliese et al.deceleration [53,54], though the use of a modeling method
designed to handle heterogeneity revealed that non-linear
trajectories are indeed common in patients with T2D [55].
It can be diagnosed using serial measurement of serum
creatinine and/or cystatin C, which allow to estimate the
slope of eGFR when it is still within the normal range
[51,52]; decliners are usually identified by an eGFR loss
3 ml/min/year, whereas a rapid progression is defined as
an eGFR loss 5 ml/min/year according to the Kidney
Disease: Improving Global Outcomes (KDIGO) guidelines
[56]. Of note, both initiation and progression of eGFR
decline may be independent of albuminuria. In fact, pro-
gressive renal decline was observed among patients with
any level of albuminuria, though it was less frequent
among individuals with normoalbuminuria (9% in T1D and
20% in T2D) than in those with microalbuminuria (22% in
TID and 33% in T2D) and macroalbuminuria (51% in TID
and 68% in T2D) [51,52,57e59]. Conversely, most of the
normoalbuminuric individuals maintained stable renal
function over time [52,58], but a substantial proportion of
non-decliners was observed also among proteinuric pa-
tients [52,59]. In addition, in both decliners and non-
decliners, albuminuria may either progress, remain sta-
ble, or regress, though progression is more frequent
among decliners and regression is more frequent among
non-decliners. Indeed, in a cohort of 79 microalbuminuric
patients with T1D, microalbuminuria progressed to mac-
roalbuminuria in 12 (50.0%) of the 24 decliners and in 10
(22.2%) of the 45 non-decliners, whereas it regressed in 3
decliners (12.5%) and 24 non-decliners (53.3%) [51].
Taken together, these findings indicate that albuminuria
and reduced eGFR may occur and proceed either together or
separately as complementary or “twin” manifestations of
DKD [60] and that there are twomain pathways for the onset
andprogressionofDKD, i.e., albuminuric andnonalbuminuric
(Fig. 1). In the classical albuminuric pathway, eGFR loss is
preceded and substantially driven by the development and
progression of microalbuminuria, the reduction of which is
therefore expected to significantly slow down renal functionFigure 1 Albuminuric and nonalbuminuric pathways of DKD pro-
gression. DKD Z diabetic kidney disease; GFR Z glomerular filtration
rate; ESKD Z end-stage kidney disease.
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nonalbuminuric renal impairment and progressive renal
decline are two sides of the same coin, eGFR loss is indepen-
dent from the onset and progression of microalbuminuria
and, hence, it may not benefit from reduction of albuminuria.
Assuch, iteitheroccurs in theabsenceofalbuminuria (orright
before or soon after the onset of microalbuminuria) or pro-
gresses toward ESKD irrespective of whether albuminuria
remains stable, progresses or reverses.
However, the level of albuminuria [61], from increments
within the normal range [62] to nephrotic range proteinuria
[63], remains a powerful independent predictor of eGFR
decline, especially in diabetic individuals with low eGFR. A
recent observational study evaluated cardiorenal risk in dia-
betic (nZ 693) versus non-diabetic (nZ 1491) patientswith
chronickidneydisease (CKD) (75%withaneGFR<45ml/min/
1.73m2), stratifiedby the level of proteinuria and followed for
a median of 4.07 years [64]. In the absence of proteinuria
(<0.15 g/24 h), diabetic patients were not exposed to an
increased risk of ESKD compared with non-diabetic in-
dividuals, whereas they had only a higher CVD risk in the
presence of moderate proteinuria (0.15e0.49 g/24 h). In
contrast, in patients with proteinuria 0.50 g/24 h, the car-
diorenal risk was primarily driven by the level of proteinuria
independent of the diabetic status [64]. Similar data have
been provided by the CRIC Study in the US that prospectively
followed 1908 patients with T1D or T2D and reduced eGFR
(meaneGFR41ml/min/1.73m2) foramedianof6.3years [40].
Complexity of this issue further increases when consid-
ering that, in the context of low eGFR, the absolute level of
proteinuria does have an intrinsic pathophysiological limita-
tion, as it dependsnotonlyon theextentof kidneydamagebut
also on the number and function of residual nephrons;
therefore, a lowproteinuria level canbemerelya consequence
of low eGFR. In this regard, a recent multi-cohort prospective
study in 3957 patients (29% with diabetes) with an eGFR
<60 ml/min/1.73 m2 has demonstrated that proteinuria
indexed to eGFR acts as an independent predictor of ESKD,
with this association being stronger than that observed with
absolute proteinuria level and in diabetic than in non-diabetic
individuals [65].
Given the strong association between albuminuria and
eGFR decline, several studies have investigated whether
reduction of albuminuria translates into improved renal
outcomes in the long-term. A pooled analysis of interven-
tional studies showed that, in both types of diabetes, the
initial decrease in albuminuria with anti-hypertensive
treatment does not predict the subsequent decline in eGFR
in early nephropathy (microalbuminuria and preserved
eGFR), but it does in advanced disease (macroalbuminuria
and reduced eGFR) [66]. In fact, in the DCCT/EDIC Study,
remission of microalbuminuria in T1D patients was not
associated with a significant reduction in the risk of adverse
outcomes, including sustained eGFR <60 ml/min/1.73 m2
[67], whereas in the ADVANCE Study, a “real” decrease in
albuminuria in T2D individuals was associated with a
significantly lower risk of a composite primary cardiorenal
outcome, but not of major renal events [68]. Conversely, a
post-hoc analysis of the Reduction of Endpoints in NIDDMew clinical and therapeutic issues. Joint position statement of the
he natural history of diabetic kidney disease and treatment of
cular Diseases, https://doi.org/10.1016/j.numecd.2019.07.017
New issues in DKD 9with the Angiotensin II Antagonist Losartan (RENAAL) Study
clearly showed that not only baseline proteinuria, but also
changes in proteinuria in the first 6 months of therapy were
related to the degree of long-term renal protection in pro-
teinuric patients with T2D [69]. Recently, an observational
study from the Stockholm CREAtinine Measurements
(SCREAM) project [70] and two patient-level meta-analyses
[71,72] including asmanyas 31,732, 29,979, and 693,816 CKD
patients (61%, 71%, and 80% with diabetes), respectively,
provided conclusive evidence that a decrease in albuminuria
is associatedwith a reduction of the subsequent risk of ESKD,
depending on the level of albuminuria [71,72]. Collectively,
current evidence supports the use of changes in albuminuria
asa surrogateoutcome in trialsdesigned to test theefficacyof
interventions aimed at halting the progression of DKD, in the
setting of increased albuminuria [73].
Despite the largebodyofevidence indicatingtheexistence
of different DKD phenotypes, it is still unclear whether the
albuminuric andnonalbuminuricDKDmodels represent true
distinct pathways underlying different pathogenic and
pathophysiological mechanisms and what is the reason for
the progressive switch from the classical albuminuric pre-
sentation to the new nonalbuminuric phenotypes, i.e., non-
albuminuric renal impairment and progressive renal decline.Box 1.1. In the last decades, two new phenotypes
have been increasingly recognized: “non-
albuminuric renal impairment”, in which eGFR
decline is not preceded by the development and
progression of microalbuminuria and may remain
the sole renal abnormality, and “progressive renal
decline”, in which eGFR loss represents the main
abnormality that develops and progresses inde-
pendently of the presence and extent of albumin-
uria and its subsequent course. These phenotypes
suggest that DKD onset and progression may occur
also through a “nonalbuminuric” pathway, distinct
from the classical “albuminuric” pathway. Howev-
er, when present, albuminuria remains a strong
predictor of eGFR decline and a main target of
renoprotective therapy, especially in the setting ofImpact of improved treatment on the natural history of
diabetic nephropathy
The opposite temporal trends in the prevalence of albu-
minuria and reduced eGFR and the increasingly divergent
presentation and course of these two main DKD mani-
festations observed over the last decades suggest that
changes in the natural history of diabetic nephropathy
may be related to changes in the type and intensity of
preventive and therapeutic interventions aimed at con-
trolling the known risk factors for the development and
progression of diabetic complications, including DKD.
Indeed, serial cross-sectional analyses of data from US
and Japanese adults with diabetes have shown an
moderate-to-severe impairment of renal function.Please cite this article as: Pugliese G et al., Diabetic kidney disease: N
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blockers, and statins, which has resulted in a progressive
improvement in glycemic, blood pressure and lipid con-
trol from the 90s to the 10s [11,12] suggesting a cause-
effect relationship with the reduction in the prevalence
of albuminuria and the increment in the prevalence of
reduced eGFR. However, while the relation with reduc-
tion of albuminuria is well established, it is difficult to
understand whether and how changes in treatment
resulted in an increment of impaired eGFR.
One possible explanation is the progressive decrease in
all-cause and CVD mortality observed in diabetic in-
dividuals as a result of improved treatment [74], which
may have favored progression toward impaired eGFR. In
addition, the increasing age of the population due to the
reduced mortality may have resulted in an increased
prevalence of reduced eGFR. However, data from the
NHANES argue against this hypothesis, as the increase in
prevalence of reduced eGFR was observed both in
younger and older individuals [11] and reduction in
mortality was confined to individuals with albuminuria
[75]. Rather, the monotonic increase in diabetes duration
with no change in mean age reported in the NHANES
cohort from 1988 to 2014 [11] suggests a progressively
earlier onset of T2D, which was found to be an indepen-
dent predictor of eGFR decline [76]. Another explanation
is the progressive lowering of average blood pressure
during the past two decades among adults with diabetes
[11,12], which may have resulted in reduction of renal
perfusion pressure and, hence, of eGFR in some in-
dividuals. Finally, the opposite temporal trends in the
prevalence of albuminuria and reduced eGFR have been
related to the use RAS blockers. These agents, in addition
to favoring the prevention and/or regression of micro/
macroalbuminuria to normoalbuminuria [9], cause a
reversible, hemodynamically-mediated eGFR drop that
may be of clinical significance [77], though in the long run
they slow down eGFR decline [78], possibly through their
anti-proteinuric effect [69]. This interpretation is sup-
ported by the finding that, during the last decades, use of
RAS blockers and prevalence of the nonalbuminuric
phenotype have increased in parallel. For instance, in the
NHANES, use of these agents (weighed % and 95% confi-
dence interval) increased from 24.4% (21.0e28.3%) in
1998-1994 to 56.2% (52.3e59.9%) in 2009e2014 [11],
whereas recent surveys reported values up to 70% or
more [32,33,35,45]. The much lower prevalence of non-
albuminuric renal impairment when patients on RAS
blockers were excluded from the analysis [39,40] is also
consistent with the concept that individuals with the
nonalbuminuric phenotype are those who either did not
develop albuminuria or were microalbuminuric at some
point of the natural history of DKD but later became
normoalbuminuric because of treatment with RAS
blockers, i.e., in the absence of anti-RAS treatment, these
patients would have presented with the classical albu-
minuric phenotype.
However, several lines of evidence argue against this
interpretation and support the existence of two distinctew clinical and therapeutic issues. Joint position statement of the
he natural history of diabetic kidney disease and treatment of
ular Diseases, https://doi.org/10.1016/j.numecd.2019.07.017
Box 1.2. Improvements in diabetes management
over the last decades, with increasing use of med-
ications, especially RAS blockers, resulting in better
glycemic, blood pressure and lipid control, have
been effective in reducing the prevalence of albu-
minuria, but not that of low eGFR. The increased
prevention and/or regression of albuminuria due to
improved treatment has unmasked the new phe-
notypes, nonalbuminuric renal impairment and
progressive renal decline, indicating the existence
of a nonalbuminuric pathway of DKD onset and
10 G. Pugliese et al.pathways, albuminuric and nonalbuminuric, to DKD
progression. First, a relation between use of RAS blockers
and remission/regression of albuminuria has emerged in
some studies [17,18], but not in others [14,19,57,58,79]. In
addition, in both cross-sectional and longitudinal studies,
the use of RAS blockers was not higher (and in some
cases it was even lower) in T1D and T2D individuals with
nonalbuminuric DKD as compared with those with
albuminuria and either preserved or reduced eGFR
[31,32,35,45,50] and a substantial proportion of patients
with the nonalbuminuric phenotype was not on these
agents [31e33,35,49,50]. These data indicate that albu-
minuric DKD may develop despite RAS blocker treatment
and that the nonalbuminuric phenotype may occur
independently of such therapy. Second, the opposite
trends in the absolute prevalence of albuminuria and
impaired eGFR are in contrast with the finding that
reducing albuminuria with RAS blockers decreases eGFR
loss in individuals with both T1D and T2D, especially in
those with proteinuria [80e82]. Third, previous studies in
T2D patients have shown that the independent correlates
of reduced eGFR and albuminuria differ between each
other, i.e., female gender, non-smoking status, age, and
diabetes duration for reduced eGFR and male gender,
former or current smoking status, hemoglobin (Hb) A1c,
body mass index, waist circumference, and retinopathy
for albuminuria [29,49,83]. Fourth, nonalbuminuric renal
impairment was found to be associated with distinct
features which recapitulate the correlates of reduced
eGFR. Studies in T2D patients have in fact shown that,
compared with individuals with the albuminuric forms,
those presenting with the nonalbuminuric phenotype
were more frequently female, non-smoker, older, and
with longer disease duration, though differences in age
and years spent with diabetes were observed only versus
individuals with albuminuric DKD with preserved eGFR
[31,32,35]. In addition, at variance with the albuminuric
forms, the nonalbuminuric phenotype showed no or
weak association with HbA1c and HbA1c variability, hy-
pertension, and the other major microvascular compli-
cation of diabetes, i.e., retinopathy, with up to
approximately 30e50% of individuals with reduced eGFR
showing neither albuminuria nor retinopathy
[22,29,32,33,35]. Studies in T1D patients have found an
association with age, but also with HbA1c, whereas no
relation was detected with smoking status [57,58].
Altogether, these findings support the concept that
changes in treatment, including but not limited to the use
of RAS blockers, have unraveled the existence of the two
pathways by differentially affecting albuminuria and
reduced eGFR. By decreasing albuminuria, improved
treatment has been effective in reducing DKD progression
through the classical albuminuric pathway. Conversely,
due to the insufficient effect of these agents on eGFR
decline, improved treatment has failed to reduce DKD
progression through the nonalbuminuric pathway but, by
favoring prevention and/or regression of albuminuria, itPlease cite this article as: Pugliese G et al., Diabetic kidney disease: N
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impairment and progressive renal decline.
In parallel with the increasing recognition of the non-
albuminuric pathway and the new albuminuria-
independent DKD phenotypes, several studies have been
performed to identify novel biomarkers of eGFR decline
which might shed light on the pathogenic mechanisms
underlying the nonalbuminuric pathway and improve
prediction of DKD progression independent of albuminuria.Biomarkers of eGFR decline beyond albuminuria
In the recent years, a number of studies in both T1D and
T2D patients have identified several serum and urine
biomarkers that correlate with eGFR decline beyond
albuminuria and other clinical variables and improve
prediction of ESKD.
An independent association between serum uric acid
levels in the high-normal range and eGFR decline was
detected in patients with both T1D [84,85] and T2D [86e92]
and also in non-diabetic individuals [93]. The association in
patients with T2D was confirmed by a recent meta-analysis
[92] and appeared to be restricted to individuals with pre-
served renal function at baseline [94]. How serum uric acid
can incite eGFR loss is not completely understood, but pro-
inflammatory mechanisms have been suggested [95]. Based
on these findings, serum uric acid has been proposed as a
target for treatment of CKD [96] and a trial with allopurinol
is currently on-going in patients with T1D [97].
Among inflammatory markers, circulating levels of
tumor necrosis factor (TNF) receptors 1 and 2, but not of
free and total TNFa, were consistently found to be asso-
ciated with eGFR decline in patients with either T1D
[98e100] or T2D [91,101e105] and to improve prediction
of ESKD when added to algorithms including clinical var-
iables [91,102]. Other markers of inflammation that were
found to be independently associated with eGFR decline
include circulating interleukin (IL)-6 [106] and C-reactive
protein [107] and urinary monocyte chemotactic protein-1
(MCP-1) [108], in patients with T2D, and multiple urinary
inflammatory markers (IL-6, IL-8, MCP-1, interferon-g-
progression which is independent of albuminuria.ew clinical and therapeutic issues. Joint position statement of the
he natural history of diabetic kidney disease and treatment of
cular Diseases, https://doi.org/10.1016/j.numecd.2019.07.017
Box 1.3. Several biomarkers, including uric acid,
markers of inflammation, especially TNF receptors
1 and 2, and markers of tubular injury have been
shown to be associated with eGFR decline inde-
pendent of albuminuria and other clinical variables.
Other independent correlates of eGFR loss include
markers of CVD and arteriosclerosis. An association
with hyperfiltration has also emerged.
New issues in DKD 11inducible protein, and macrophage inflammatory protein-
1d) in patients with T1D [109].
Markers of tubular injury have also been associated
with eGFR decline in both types of diabetes. In detail, the
following markers were found to be independent pre-
dictors of eGFR loss: serum kidney injury molecule-1
(KIM-1), in patients with T1D [110], and urinary levels of
KIM-1 [111e113], b2-microglobulin [113], liver-type fatty
acidebinding protein (FABP) [114], and nonalbumin pro-
tein [115], and serum retinol-binding protein 4 (RBP4)
[107], in patients with T2D. However, other studies failed
to demonstrate an independent association of markers of
tubular injury with eGFR decline [116,117].
Other biomarkers that have been associated with eGFR
loss include: urinary high molecular weight adiponectin
[118], adiponectin [119], type IV collagen [120,121], and
haptoglobin [122,123]; circulating arginine vasopressin, as
measured as copeptin [124], adipocyte FABP [125], fibro-
blast growth factor 21 [126], kininogen and kininogen
fragments [127], the angiogenic factor leucine-rich a-2
glycoprotein 1 [128], the anti-ageing hormone soluble
Klotho (low levels) [129], and leptin (both high and low
levels) [130]; and erythrocyte total polyunsaturated fatty
acids (PUFAs), n-3 PUFAs, and n-3/n-6 PUFA ratio, but not
n-6 PUFAs (low levels) [106], all in T2D patients (except
urinary collagen IV, in both T1D and T2D individuals). In
addition, CKD273, a multidimensional urinary proteome
classifier consisting of 273 protein fragments, predicted
deterioration of renal function in patients with [131] and
without [132] albuminuria and also development of
microalbuminuria in normoalbuminuric individuals [133].
Finally, panels of multiple markers representing different
disease pathways and including inflammatory and tubular
biomarkers, were shown to improve prediction of eGFR
decline in patients with T2D beyond traditional risk factors
[134e139].
An association with eGFR decline was described also for
CVD biomarkers, especially high-sensitivity troponin T
[140] and left ventricular ejection fraction [141], possibly
reflecting the contribution of chronic cardiac dysfunction
to progressive eGFR impairment in the context of type 2
cardio-renal syndrome [142]. In addition, arterial stiffness,
a marker of arteriosclerosis, was found to be negatively
associated with eGFR [143] and to independently predict
eGFR decline [141,144], possibly reflecting the contribution
of highly pulsatile pressure and flow to small vessel dis-
ease in the kidney [145]. Moreover, renal function decline
in T2D individuals was found to be associated with mul-
tiple modifiable CVD risk factors [146] and with presence
of non-alcoholic fatty liver disease [147].
Finally, hyperfiltration, which has been hypothesized to
predispose to irreversible nephron damage [148], was also
found to be associated with eGFR decline in both T1D [149]
and T2D [150] patients, thus suggesting that it may serve
as a predictor of eGFR loss.
These findings indicate that eGFR decline is associated
with multiple pathways which may specifically impact on
renal function independent of albuminuria and drive DKDPlease cite this article as: Pugliese G et al., Diabetic kidney disease: N
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pathway.Pathogenic mechanisms and anatomical correlates of
eGFR decline independent of albuminuria
The clinical and biochemical features associated with
nonalbuminuric renal impairment and progressive renal
decline support the concept that the pathogenesis of these
phenotypes differs from that of the albuminuric ones and
suggest the involvement of mechanisms operating mainly
at the vascular and/or tubulo-interstitial level.
The hypothesis of a predominant (macro)vascular na-
ture of lesions underlying these phenotypes is supported
by the weak or no association of nonalbuminuric renal
impairment with diabetic retinopathy and HbA1c
[22,32,151] and by the relationship of eGFR decline with
CVD biomarkers and arterial stiffness, suggesting the
involvement of intrarenal arteries. This is more likely in
individuals with T2D, who present with several CVD risk
factors in addition to hyperglycemia, including hyperten-
sion, dyslipidemia, central obesity, and aging itself, all of
which may contribute to renal injury, though to a varying
extent in each individual [4,152].
The hypothesis of a predominant tubulo-interstitial
nature of lesions underlying these phenotypes is sup-
ported by the association of eGFR decline with uric acid
[84e94] and markers of inflammation [91,98e109] and
tubular injury [110e115]. In addition, two small studies in
patients with biopsy-proven diabetic nephropathy
showed that the score for interstitial fibrosis and tubular
atrophy was an independent predictor of eGFR decline
[153,154]. It has been suggested that unresolved and/or
repeated episodes of acute kidney injury (AKI) may
contribute to eGFR decline in diabetic individuals [4],
consistent with the demonstration that AKI is a risk factor
for future development (or progression) of CKD,
depending on its severity, duration, and frequency [155].
Though this hypothesis is unlikely in T1D patients,
because eGFR trajectories were shown to be mostly linear
in these individuals [53], it cannot be excluded in patients
with T2D [156], who are more susceptible to AKI because
of the presence of several additional risk factors, such as
preexisting CKD, advanced age, heart failure, and hyper-
tension [155,157].ew clinical and therapeutic issues. Joint position statement of the
he natural history of diabetic kidney disease and treatment of
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Box 1.4. It has been hypothesized that the non-
albuminuric phenotype is associated with atypical
vascular and/or tubulo-interstitial lesions, instead of
the typical glomerular lesions. Unfortunately, there
are no or insufficient renal biopsy data to confirm
this hypothesis, though the available data indicate a
wide heterogeneity of anatomical features in pa-
tients with T2D, but not in those with T1D, who
almost invariably present with the classical
glomerular lesions. Research biopsy studies spe-
cifically focused on the nonalbuminuric phenotype
are therefore required.
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opsy data to confirm the hypothesis of prevailing
(macro)vascular and/or tubulo-interstitial lesions un-
derlying the nonalbuminuric pathway, as compared to
the typical microvascular lesions with predominant
glomerular injury (glomerular basement membrane
thickening, mesangial expansion, and nodular or diffuse
glomerulosclerosis) characterizing the classical albu-
minuric pathway. In virtually all the available studies,
renal biopsy was in fact performed for diagnostic pur-
poses, i.e., in the presence of features raising suspicion
of a non-diabetic renal disease such as glomerulone-
phritis, which was in fact highly prevalent, either iso-
lated or in combination with diabetic nephropathy, as
shown by a pooled meta-analysis of 48 studies
including 4678 diabetic individuals, mainly with T2D
[158]. In addition to exhibiting an atypical presentation
and/or course of renal disease, virtually all patients
included in these studies had albuminuria and most of
them were proteinuric; therefore, no conclusion can be
drawn regarding the anatomic substrate of non-
albuminuric renal impairment and research biopsy
studies specifically focused on this phenotype are
therefore required [159]. The only available study with
these characteristics reported on renal biopsies from 31
T2D patients with reduced eGFR and either normoal-
buminuria (n Z 6, 19.4%), microalbuminuria (n Z 8,
25.8%) or macroalbuminuria (n Z 17, 54.8%). Results
showed that individuals with micro/macro albuminuria
had typical glomerular lesions, whereas half of those
with normoalbuminuria showed atypical (vascular and/
or tubulo-interstitial) or no lesions, but the other half
still presented with diabetic glomerulosclerosis, though
associated with varying degrees of arteriosclerosis [160].
Another study including 260 Japanese T2D patients
with biopsy-proven diabetic nephropathy showed that
glomerular lesions were associated with albuminuria,
whereas glomerular, tubulo-interstitial, and vascular
lesions were associated with reduced eGFR and were
more advanced in individuals with normoalbuminuria
and impaired renal function than in those with nor-
moalbuminuria and preserved eGFR [161]. In addition,
among patients with reduced eGFR, those with nor-
moalbuminuria showed tubulo-interstitial and vascular
lesions similar to or more advanced than glomerular
lesions, compared with those with micro or macro-
albuminuria [161]. However, a wide heterogeneity of
renal lesions was observed also in a previous study on
34 microalbuminuric T2D patients with preserved eGFR,
with 10 individuals (29.4%) showing no lesions, 10
(29.4%) showing typical glomerular lesions, and 14
(41.2) showing vascular and/or tubulo-interstitial le-
sions; interestingly, both HbA1c levels and prevalence of
retinopathy were higher in those with typical lesions
[162]. Thus, atypical histological features are not spe-
cific of nonalbuminuric renal impairment, though
probably more frequent in patients presenting with this
phenotype, and vice versa typical lesions are not spe-
cific of the albuminuric form. Indeed, the Cohen rat, aPlease cite this article as: Pugliese G et al., Diabetic kidney disease: N
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shows only typical glomerular lesions [163]. Moreover,
classical glomerulopathy can be detected in virtually all
T1D patients with more than 5-year duration [164] and,
in a more severe form, among those with normoalbu-
minuria and reduced eGFR [165]. No biopsy data are
available from individuals showing early and rapid
progressive renal decline, except for the finding that, in
a small sample of Chinese T2D patients with renal bi-
opsy, accelerated eGFR decline was predominantly
associated with diabetic glomerulosclerosis [55].
Thus, at present, the clinical phenotype cannot be
related to a specific anatomical phenotype, with presence
or absence of albuminuria corresponding to typical
glomerular and atypical vascular and/or tubulo-interstitial
lesions, respectively. However, regardless of the anatom-
ical substrate of the new phenotypes, the heterogeneity in
the clinical presentation and course of DKD has important
implications for the diagnosis, prognosis, and possibly
treatment of this complication.Diagnostic, prognostic and therapeutic implications
Current guidelines recommend to assess both albumin-
uria and eGFR for the screening of DKD [5]. Albuminuria
should be measured preferably as urinary albumin-to-
creatinine ratio (UACR) in a spot urine sample [56], in
the absence of symptoms and signs of urinary tract
infection or other interfering clinical conditions [56].
Assessment of urinary albumin excretion rate (UAER) in
timed or 24-hour collections is more troublesome but not
more accurate than UACR, whereas measurement of al-
bumin concentration in spot urine samples without
simultaneously measuring urine creatinine is less
expensive but also less accurate. Because of biological
variability in albuminuria, two of three specimens of
UACR (or UAER) collected within a 3- to 6-month period
should be abnormal before considering a patient to have
albuminuria, though in T2D individuals from the RIACE
cohort concordance rate between the first value and the
geometric mean of two-to-three measurements was
>90% for all albuminuria categories [166]. eGFR should be
calculated from serum creatinine using a validatedew clinical and therapeutic issues. Joint position statement of the
he natural history of diabetic kidney disease and treatment of
cular Diseases, https://doi.org/10.1016/j.numecd.2019.07.017
New issues in DKD 13formula, preferably the CKD-EPI equation [56]. The
emergence of the progressive renal decline phenotype
suggests the importance of monitoring changes of eGFR
over time to identify individuals experiencing an eGFR
loss when their renal function is still within the normal
range. To this end, though cystatin C-based eGFR [167] or
cystatin C- and creatinine-based eGFR [168] may be
preferable, serial measurements of serum creatinine may
be sufficient, provided that they are frequent (at least
once a year) and extend over a period of 3e5 years [52].
The diagnosis of DKD is usually made clinically, based
on the presence of albuminuria and/or reduced eGFR,
consistent with the finding that absence of albuminuria is
a common feature in diabetic individuals with renal
dysfunction. Currently, a renal biopsy for diagnostic pur-
poses is indicated in case of atypical presentations that
suggest the presence of other renal disorders which may
benefit from specific treatment. Clinical features which
raise suspicion of a non-diabetic renal disease include
acute onset of proteinuria or rapid worsening of renal
function, diabetes duration <5 years (only for T1D pa-
tients), absence of retinopathy (which however is
frequently lacking also in T2D individuals with DKD,
especially in those without albuminuria), presence of
active urine sediment (red or white blood cells or cellular
casts), and symptoms or signs of other systemic diseases
[3]. Though the real prevalence of non-diabetic renal dis-
ease in diabetic individuals is probably <10% [1], this
possibility should be always considered and a renal biopsy
should be performed in the presence of the criteria listed
above [159]. Conversely, a renal biopsy in patients with
nonalbuminuric DKD is not indicated at present, though
studies are urgently required for research purposes to
understand the anatomical bases of this increasingly
common phenotype [159].
Based on the level of albuminuria and eGFR, patients
should then be assigned to the corresponding risk cate-
gory according to the KDIGO CKD classification, which
serves as a guide for frequency of monitoring and in-
dicates the risk of progression to ESKD, but also of CVD
events [56]. In fact, it has long been recognized that CKD
from any cause is associated with a two-to-four-fold
increased risk of morbidity and mortality from CVD
since its early pre-dialytic stages, independent of tradi-
tional CVD risk factors [169]. In both T1D [170,171] and
T2D [23,172], DKD represents a major contributor to
excess all-cause and CVD death, possibly as a mediator of
the relationship between hyperglycemia and adverse
outcomes. While DKD-related mortality risk is much
higher in younger individuals, DKD appears to fully ac-
count for excess risk of death associated with T2D only in
older patients [172,173]. Both albuminuria and reduced
eGFR were shown to be associated with all-cause and CVD
mortality, independently of each other, both in the general
population [174e177] and in patients with T1D [171,178]
and T2D [42,172,173].
Recent reports have examined the mortality risk
associated with the different DKD phenotypes in pa-
tients with T2D. A post-hoc analysis of the ADVANCEPlease cite this article as: Pugliese G et al., Diabetic kidney disease: N
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death associated with nonalbuminuric DKD was similar
to that of microalbuminuria with an eGFR 90 ml/min/
1.73 m2, but lower than that of microalbuminuria
with an eGFR 60e89 ml/min/1.73 m2 and of macro-
albuminuria with an eGFR >60 ml/min/1.73 m2 [42].
Conversely, a post-hoc analysis of the FIELD Study (9795
T2D participants) showed that the nonalbuminuric
phenotype was associated with a higher risk of death
from CVD, non-CVD, and any cause, compared with
microalbuminuria with an eGFR >60 ml/min/1.73 m2
and macroalbuminuria with an eGFR 90 ml/min/1.73 m2
[41]. However, due to the selection criteria for trial entry,
only a limited number of individuals with an eGFR
<60 ml/min/1.73 m2 were enrolled in these two studies.
The community-based Casale Monferrato Study (1565
patients with T2D) reported a significant association
between reduced eGFR and mortality only among mac-
roalbuminuric individuals [179]. In contrast, data from
the NHANES 1988e1994 (1430 diabetic individuals)
showed that the standardized 10-year mortality among
patients with the nonalbuminuric phenotype was inter-
mediate between the albuminuric DKD phenotypes with
preserved and reduced eGFR [23]. In the Cardiovascular
Health Study (691 older diabetic adults), the adjusted
risk of death was similar for albuminuria alone and
reduced eGFR alone [180]. Likewise, data from the RIACE
cohort (15,773 T2D patients) showed that risk of death
of reduced eGFR alone was similar to that of albuminuria
alone. Moreover, in normoalbuminuric patients with an
eGFR 45e59 ml/min/1.73 m2, risk was similar to that of
patients with microalbuminuria alone and, in those with
an eGFR <45 ml/min/1.73 m2, risk was similar to that of
patients with macroalbuminuria alone [181]. Finally, a
recent analysis of the NHANES 2003e2006 data showed
that age-standardized mortality risk for nonalbuminuric
DKD was lower than for macroalbuminuria with eGFR
60e89 60 ml/min/1.73 m2, but higher than for micro-
albuminuria alone and macroalbuminuria with eGFR
90 ml/min/1.73 m2 [75]. Noteworthy, this analysis also
showed that mortality rates in adults with diabetes have
decreased among individuals with increased albumin-
uria and increased in those with decreased eGFR and
normoalbuminuria from 1988 to 2006 [75]. These
diverging temporal trends in mortality might also explain,
at least partly, the differences in the risk of death asso-
ciated with isolated albuminuria and reduced eGFR
among the above studies. Similar findings have been re-
ported in patients with T1D. In the FinnDiane Study,
the nonalbuminuric phenotype was associated with an
increased risk of CVD and all-cause mortality to the
same extent as individuals with albuminuria alone [45].
Likewise, in a study from Tuscany, the risk of all-cause
death associated with reduced eGFR alone was similar
to that of increased albuminuria alone, with the highest
mortality occurring in T1D patients with both reduced
eGFR and albuminuria [182].
Regarding CVD events, data from the RIACE cohort
have shown that the age- and gender-adjustedew clinical and therapeutic issues. Joint position statement of the
he natural history of diabetic kidney disease and treatment of
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Box 1.5. Diagnosis of DKD is based on both albu-
minuria and eGFR, preferably calculated using the
CKD-EPI equation. Albuminuria should be
confirmed in two of three urine specimens collected
within a 3- to 6-month period, whereas the slope of
eGFR should be calculated from frequent mea-
surements of serum creatinine and/or cystatin C,
starting when renal function is normal. A renal bi-
opsy should be performed when there is suspicion
of a non-diabetic renal disease. Prognosis of DKD is
influenced by the increased risk of progression to-
ward ESKD as well as of morbidity and mortality
from CVD. Compared with the classical albuminuric
phenotype, the nonalbuminuric phenotype is asso-
ciated with an equal CVD risk, whereas risk of pro-
gression to ESKD is lower. Treatment of DKD is
effective in reducing albuminuria, but not eGFR
decline, suggesting that these two DKD manifesta-
tions may require different therapeutic strategies,
though there are no data from clinical trials on in-
dividuals with nonalbuminuric renal impairment or
progressive renal decline.
14 G. Pugliese et al.thresholds at which CVD burden increases in T2D in-
dividuals stand near to or within the normal range for
both eGFR (78.2 ml/min/1.73 m2) and albuminuria
(10.5 mg/24 h). Moreover, the prevalence of any CVD
event was intermediate in the nonalbuminuric pheno-
type, i.e. higher than that of albuminuria alone and lower
than that of combined albuminuria and reduced eGFR.
Interestingly, coronary events correlated more strongly
with the nonalbuminuric phenotype than with the
albuminuric forms, whereas the opposite was observed
for cerebrovascular and peripheral events [183]. The
ADVANCE Study showed that, over a 4.3-year follow-up,
the hazard ratio for CVD events was similar for reduced
eGFR and albuminuria, whereas it was markedly higher
when both abnormalities were present [42]. Regarding
renal outcomes, the absence of albuminuria was found to
be associated with a lower risk in patients with T2D from
the CRIC Study [40] and the ADVANCE Study [42] and
also in individuals with T1D from the FinnDiane Study
[45]. Similar results were previously obtained in a small
study showing that, over a 38-month follow-up, no
normoalbuminuric patient with reduced eGFR died or
developed ESKD, as opposed to 5 patients with micro-
albuminuria and 17 with macroalbuminuria [184]. Like-
wise, the analysis of a population-based district diabetes
registry showed that the annual eGFR decline was 0.3% in
normoalbuminuric, 1.5% in microalbuminuric, and 5.7% in
macroalbuminuric patients with T1D and T2D and a
mean eGFR >75 ml/min/1.73 m2 [61].
Thus, though less prone to progress to ESKD, the non-
albuminuric phenotype appears to be associated with a
significant risk of CVD morbidity and mortality, which is
equal to or even higher than that associated with albu-
minuria alone and requires a higher level of attention and
care than that generally provided.
Concerning therapeutic measures, the increasing prev-
alence of reduced eGFR [11,12] and the increasing mor-
tality associated with it, especially in the absence of
albuminuria [75], indicate that changes in treatment,
particularly the increasing use of RAS blockers, have not
impacted favourably on eGFR decline and the non-
albuminuric phenotype. This implies that albuminuria and
eGFR loss may require different therapeutic interventions
and that treatments which are effective in slowing down
eGFR decline are urgently required.
Thus, on purely theoretical grounds, use of angiotensin
converting enzyme (ACE) inhibitors and angiotensin re-
ceptor blockers (ARBs) may not be indicated in individuals
presenting with the nonalbuminuric phenotype, and may
even be deleterious as these agents increase susceptibility
to renal ischemia by preventing the rise of efferent arte-
riolar resistance [185]. Unfortunately, there are no data
supporting this assumption, due to the lack of intervention
trials specifically targeting individuals with the non-
albuminuric phenotype. So far, studies have in fact
included almost exclusively patients with micro or mac-
roalbuminuria in order to assess the efficacy of an inter-
vention in favouring regression or blocking progression ofPlease cite this article as: Pugliese G et al., Diabetic kidney disease: N
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and ARBs were shown to provide similar benefits [186,187]
and to be effective beyond their blood pressure-lowering
effect in preventing progression to ESKD in patients with
macroalbuminuria [80e82], but not in the setting of lower
levels of albuminuria [188,189].Treatment of hyperglycemia in T2D patients with
impaired renal function
Treatment of hyperglycemia in patients with T2D and
impaired renal function represents a major challenge for a
number of reasons, which may impose avoidance/discon-
tinuation or dose adjustment of certain anti-
hyperglycemic drugs. First, together with the liver, the
kidney is a major site for drug metabolism and excretion
[190]. This implies that circulating levels of agents that are
degraded and/or eliminated via the renal route may in-
crease in these individuals, thus enhancing the risk of
adverse effects including hypoglycemia. Second, impaired
renal function per se is a risk factor for hypoglycemia, even
in non-diabetic individuals [191], as the kidney contributes
to total endogenous glucose production by approximately
30% [192]. In addition, in individuals with impaired renal
function, hypoglycemia is favored by the coexistence of
acidosis, which limits the ability of the liver to compensate
for reduced renal gluconeogenesis [193] as well as of
malnutrition and/or muscle wasting, which decrease he-
patic glycogen stores and the availability of gluconeogenic
substrates [194]. Third, as patients with impaired renal
function are usually excluded from clinical trials, evidenceew clinical and therapeutic issues. Joint position statement of the
he natural history of diabetic kidney disease and treatment of
cular Diseases, https://doi.org/10.1016/j.numecd.2019.07.017
New issues in DKD 15on the efficacy and safety of several anti-hyperglycemic
agents is lacking in these individuals, especially in those
with an eGFR <30 ml/min/1.73 m2 [195]. Finally, as
compared with patients without DKD, those with DKD are
usually older, with longer diabetes duration, more
frequently suffering from comorbidities, especially CVD,
[196] and, hence, on multiple medications with potential
interactions with anti-hyperglycemic drugs [197].
Nevertheless, the therapeutic options for T2D in-
dividuals with impaired renal function have substantially
increased over the last decades. On the one hand, severalFigure 2 Recommended usage and dosage of currently available non-insu
filtration rate; DPP-4 Z dipeptidyl peptidase 4; GLP-1 Z glucagon-like pep
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recently made available for treatment of T2D [198]. Of
these, the glucagon-like peptide 1 (GLP-1) receptor ago-
nists and the dipeptidyl peptidase 4 (DPP-4) inhibitors can
be used safely in individuals with impaired renal function,
whereas the use of the inhibitors of sodium-glucose
cotransporter 2 (SGLT2) is limited [199]. In addition,
these new agents do not cause hypoglycemia, except when
used in combination with insulin and/or insulin secreta-
gogues, and, more importantly, cardiovascular outcome
trials have shown that, along with cardiovascular benefits,lin drugs according to the level of eGFR. eGFR Z estimated glomerular
tide 1; SGLT2 Z sodium-glucose cotransporter 2.
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16 G. Pugliese et al.GLP-1 receptor agonists and SGLT2 inhibitors provide also
renal protection, thus opening promising perspectives for
the prevention and treatment of DKD [200]. Of note, renal
protection from GLP-1 receptor agonists was limited to
reduced progression of albuminuria, whereas SGLT2 in-
hibitors appeared to slow down also the decline of eGFR,
though renal outcomes were not primary endpoints in
these trials [200]. On the other hand, recent real-world
data have shown a widespread use of old drugs such as
metformin and sulfonylureas in patients with reduced
renal function, even beyond the current labeling contra-
indications [201]. Nevertheless, these data have also
shown that, in these individuals, risk of lactic acidosis with
metformin is lower than expected [202], thus prompting
reconsideration of its use in patients with moderately
reduced renal function, who would otherwise be excluded
from the beneficial effects of this agent [5].
Figure 2 shows the recommended usage and dosage of
currently available non-insulin drugs according to the level
of eGFR.Box 2. Treatment of hyperglycemia in T2D patients
with impaired renal function represents a major
challenge for a number of reasons, which may
impose avoidance/discontinuation or dose adjust-
ment of certain anti-hyperglycemic drugs. The
therapeutic options for T2D patients with impaired
renal function have substantially increased over the
last decades, due to the availability of several new
classes of anti-hyperglycemic drugs, which do not
cause hypoglycemia and, in some cases, seem to
provide cardiorenal protection, and to the recon-
sideration of the use of old drugs such as metfor-
min in these individuals.
Box 2.1. Insulin treatment with both human prepa-
rations and insulin analogs is safe in all eGFR cat-
egories, though it may be necessary to reduce the
dosage in patients with advanced renal dysfunction.
The use of the insulin secretagogues sulfonylureas
and meglitinides should be limited in patients with
impaired renal function because of the increased
risk of hypoglycemia. Glibenclamide should be
avoided, glimepiride should be avoided or initiated
conservatively at 1 mg daily, and gliclazide, glipi-
zide, and repaglinide should be used with caution at
reduced dose.Insulin and insulin secretagogues
Due to the increased risk of hypoglycemia associated with
renal dysfunction, insulin and insulin secretagogues should
be used with caution in patients with reduced eGFR.
Nevertheless, insulin treatment with both human
preparations and insulin analogs is safe in all eGFR cate-
gories, though it may be necessary to reduce the dosage in
patients with advanced renal dysfunction, especially for
human insulins, which are metabolized by insulinase in
both the liver and kidney [203]. The reduction in insulin
clearance has been estimated to range between 10 and 20%
in patients with moderate-to-severe CKD [204].
Conversely, the use of the insulin secretagogues sulfo-
nylureas and meglitinides, which stimulate insulin release
by the b-cell in a glucose-independent manner [205],
should be limited in patients with impaired renal func-
tion, though to a various extent depending on the specific
compound. Glibenclamide (also known as glyburide)
should be avoided in patients with any degree of renal
impairment [5,199,206], because of its long duration ofPlease cite this article as: Pugliese G et al., Diabetic kidney disease: N
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resulting from hepatic metabolism of the drug [207]. For
the same reasons [208], glimepiride should be avoided or
initiated conservatively at 1 mg daily in patients with
reduced eGFR [5,199,206]. Gliclazide and glipizide are not
contraindicated in patients with renal dysfunction, since
they are metabolized by the liver and excreted in the
urine as inactive metabolites [209,210]; however, caution
is recommended also for these agents [5,199,206] and
glipizide should be initiated conservatively at 2.5 mg daily
in patients with reduced eGFR [5]. Finally, the meglitinide
repaglinide is a short-acting secretagogue that is also
metabolized by the liver to inactive metabolites, which are
excreted via the bile into the feces [211]. For these rea-
sons, repaglinide is largely utilized across all eGFR cate-
gories, despite the increased risk of hypoglycemia, which
becomes relevant for low levels of eGFR (<30 ml/min/
1.73 m2). Therefore, repaglinide should be initiated
conservatively at 0.5 mg [5,199,206] and the dose should
be adjusted or the drug substituted with a safer agent
such as a DPP-4 inhibitor in case of declining eGFR.Insulin sensitizers and inhibitors of a-glycosidase
The insulin sensitizers, biguanides and thiazolidinediones,
and the inhibitors of a-glycosidase are associated with low
risk of hypoglycemia.
Among the insulin sensitizers, the biguanide metformin
is the first-line drug for the treatment of T2D [5], albeit its
mechanism of action is still debated [212], with an increas-
ingly recognized effect at the gut level in addition to that in
the liver [213]. As metformin is not metabolized by the liver
and is excreted unchanged by the kidney [214], its plasma
concentrations rise in patients with renal impairment;
therefore, it is contraindicated in these individuals, though
the eGFR threshold has been lowered to <30 ml/min/
1.73 m2 [5,199,206,215]. Moreover, metformin should be
used at reduceddose (byapproximately 50%) or it shouldnot
be started in patients with an eGFR 30e45 ml/min/1.73 m2,
whereas nodose adjustment is required for an eGFR>45ml/
min/1.73 m2 [5,199,206,215]. Pending the results of ongoing
clinical trials, even less stringent eGFR thresholds might be
recommended for delayed-release metformin preparationsew clinical and therapeutic issues. Joint position statement of the
he natural history of diabetic kidney disease and treatment of
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New issues in DKD 17that target the ileum, which minimize systemic exposure
while maintaining glucose-lowering efficacy [216].
Conversely, conditions characterized by lactate over-
production from hypoxic tissues, as in respiratory and cir-
culatory failure and severe anemia, and/or impaired lactate
removal due to impaired gluconeogenesis, as in advanced
liver disease, may precipitate lactic acidosis in individuals
with reduced renal function treated with metformin and,
hence, require drug discontinuation [216].
Pioglitazone, the only thiazolidinedione compound
currently available for clinical use in most European coun-
tries, activates peroxisome proliferator-activated receptor g,
a nuclear receptor regulating the transcription of genes
involved in glucose and lipid metabolism, thus increasing
insulin sensitivity [217]. It is metabolized entirely by the
liver [218] and, hence, no dose adjustment is required ac-
cording to the level of eGFR [5,199,206]. However, caution is
recommended in patients with advanced renal dysfunction,
due to the increased risk offluid retention, anemia, and bone
fragility characterizing these individuals, which may be
enhanced by the use of pioglitazone [5,199,206].
Acarbose is an inhibitor of a-glycosidase that splits
polysaccharides into monosaccharides, thus delaying in-
testinal glucose absorption and reducing post-prandial
glycaemia [219]. It is metabolized by intestinal bacteria,
with production of several metabolites, at least one of
which has some biological activity; however, only a small
amount of the drug is absorbed [220] and less than 2% is
recovered in the urine as an active drug, either intact
compound or active metabolite [221]. For this reason and
for the limited evidence in patients with severe renal
insufficiency, acarbose should be avoided in individuals
with an eGFR <30 ml/min/1.73 m2 [5,199,206].Box 2.2. Metformin is contraindicated in patients
with an eGFR <30 ml/min/1.73 m2 and in conditions
characterized by lactate overproduction from hyp-
oxic tissue and/or impaired lactate removal. It
should be used at reduced dose (by approximately
50%) or should not be started in individuals with an
eGFR 30e45 ml/min/1.73 m2. Pioglitazone can be
used without dose adjustment, though caution is
recommended in patients with advanced renal
dysfunction, due to the increased risk of fluid
retention, anemia, and bone disease. Acarbose
should be avoided in individuals with an eGFR
<30 ml/min/1.73 m2.
Box 2.3. The DPP-4 inhibitors can be used in pa-
tients with impaired renal function, albeit at
reduced dosage (except for linagliptin, which does
not require dose adjustment), are weight neutral
and have an excellent safety profile. The GLP-1 re-
ceptor agonists can be used up to an eGFR of 30 ml/
min/1.73 m2 (exenatide and lixisenatide) or 15 ml/
min/1.73 m2 (liraglutide and dulaglutide), favor
weight loss and provide protection from cardio-
vascular and renal disease (the latter limited to
albuminuria), but their use may be associated with
gastro-intestinal symptoms.Incretin mimetics
The incretin mimetics include the DPP4 inhibitors, which
block the DPP4-mediated breakdown of the incretins GLP-
1 and gastric inhibitory polypeptide (GIP), thus increasing
and maintaining endogenous GLP-1 and GIP levels, and the
GLP-1 receptor agonists, which are DPP4-resistant incretin
analogues derived from exendin-4 or human GLP-1 [222].
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secretion in a glucose-dependent manner, thus reducing
blood glucose levels without causing hypoglycemia [222].
In addition, by virtue of the pharmacological incretin
levels achieved with GLP-1 receptor agonists, these agents
reduce appetite by delaying gastric emptying and inhib-
iting hypothalamic orexigenic signaling and, hence, pro-
duce body weight loss [223].
All the DPP-4 inhibitors are metabolized by the liver,
though to a different extent, and are excreted by the kid-
ney, with the exception of linagliptin, onlyw5% of which is
found in the urines [224]. Therefore, while dosage of
sitagliptin, vildagliptin, saxagliptin, and alogliptin should
be reduced according to the level of eGFR, linagliptin re-
quires no dose adjustment [5,199,206]. However, all the
DPP-4 inhibitors can be used safely in patients with renal
dysfunction and, except saxagliptin, even in those on
dialysis [5,199,206]. The excellent safety profile of these
agents, including the very low risk of hypoglycemia, makes
them the first treatment option in elderly patients with
reduced renal function and mild-to-moderate metabolic
derangement who do not require specific cardiovascular
protection [225]. In these individuals, they should be
preferred to secretagogues, including repaglinide.
Among the GLP-1 receptor agonists, only the exendin-4-
derived exenatide and lixisenatide are excreted by the
kidney and, hence, these agents should be avoided if eGFR
is < 30 ml/min/1.73 m2. Conversely, the human GLP-1-
derived liraglutide and dulaglutide can be used up to an
eGFR of 15 ml/min/1.73 m2, whereas there is insufficient
experience with these agents for lower eGFR values [226].
Use of these agents may be associated with gastrointestinal
symptoms, which however tend to disappear with time
[227]. Due to their robust glucose-lowering activity, they
represent an effective and safe alternative to insulin or, in
combination with basal insulin, to basal-bolus regimens, to
reduce the risk of hypoglycemia and body weight gain
[225]. In addition, they are a first-line treatment in obese
patients and in those with atherosclerotic cardiovascular
disease because of their cardiovascular benefits [225]. In
order to provide renal protection, they may be used also in
patients with albuminuria and an eGFR <60 or 45 ml/min/
1.73 m2 as an alternative to SGLT2 inhibitors [225].ew clinical and therapeutic issues. Joint position statement of the
he natural history of diabetic kidney disease and treatment of
ular Diseases, https://doi.org/10.1016/j.numecd.2019.07.017
Box 2.5. Treatment of patients with impaired renal
function with anti-hyperglycemic agents which
need dose adjustment or discontinuation below
certain eGFR thresholds require regular eGFR
monitoring. In case of instability of eGFR over time
these agents should not be used.
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The SGLT2 inhibitors act at the kidney level by inhibiting
glucose (and sodium) reabsorption in the proximal tubule,
thus causing glycosuria, osmotic diuresis and, at least
initially, natriuresis [228]. Energy loss with glycosuria
produces weight loss, whereas water loss with diuresis
results in volume depletion and reduction of blood pres-
sure [228]. Adverse effects include genital and urinary
tract infections, symptoms of volume depletion, and
euglycemic ketoacidosis [229]. As glucose reabsorption by
the proximal tubule is linearly related to blood glucose
levels and glucose filtration by the glomerulus, the SGLT2
inhibitors do not cause hypoglycemia, but display insuffi-
cient glucose-lowering effect in individuals with reduced
eGFR [230]. Therefore, these agents should not be initiated
or should be discontinued for an eGFR <60 or 45 ml/min/
1.73 m2, respectively; in addition, dose of empagliflozin
and canagliflozin should be reduced at 10 and 100 mg
daily, respectively, if eGFR is 45e59 ml/min/1.73 m2
[5,199,206]. Though less potent than GLP-1 receptor ago-
nists, the SGLT2 inhibitors may be used to reduce insulin
requirements and the risk of hypoglycemia in insulin-
treated patients [228]. More importantly, they are indi-
cated in obese patients and represent a first-choice treat-
ment option in those with atherosclerotic cardiovascular
disease, chronic heart failure, and/or DKD, provided that
eGFR is adequate [228]. Since cardiovascular outcome tri-
als with SGLT2 inhibitors showed that cardiorenal pro-
tection and the blood pressure (and body weight) reducing
effects were maintained in patients with an eGFR <60 ml/
min/1.73 m2 [231], current eGFR limits for use of these
agents might be reconsidered in the future. The positive
results of a recent clinical trial conducted in CKD in-
dividuals with renal outcomes as primary endpoints [232]
provide further support to this concept.Box 2.4. The SGLT2 inhibitors can be used up to an
eGFR of 45 ml/min/1.73 m2, as they display insuffi-
cient glucose-lowering effect below this level, favor
weight loss and provide protection from cardio-
vascular and renal disease (the latter extended to
eGFR loss), but their use may be associated with
side effects.Additional considerations
The above mentioned eGFR thresholds below which some
anti-hyperglycemic agents should be used at reduced
dosage or even discontinued imply that renal function
should be regularly monitored in patients with T2D, at
intervals depending on the actual eGFR level and its sta-
bility over time. In addition, patients should be advised to
stop the medication in cases of dehydration, which may
abruptly reduce eGFR and increase the risk of drug side
effects. This is particularly important for treatment withPlease cite this article as: Pugliese G et al., Diabetic kidney disease: N
Italian Diabetes Society and the Italian Society of Nephrology on “T
hyperglycemia in patients with..., Nutrition, Metabolism & Cardiovasagents favoring dehydration by causing gastrointestinal
symptoms such as nausea, vomiting, and diarrhea, i.e.,
metformin, acarbose, and GLP-1 receptor agonists, or
increased diuresis, such as the SGLT2 inhibitors. In case of
eGFR instability over time, anti-hyperglycemic agents
which need dose adjustment or discontinuation below
certain eGFR thresholds should not be used.Conclusions
During the last decades, the unique heterogeneity of the
natural history of DKD has progressively emerged, possibly
as a result of improved treatment. In particular, two new
phenotypes, nonalbuminuric renal impairment and pro-
gressive renal decline, have been described. However,
though these phenotypes have been increasingly recog-
nized, their pathogenesis and anatomical correlates are
still unclear and require further investigation and per-
forming of research biopsy studies.
In the same time period, several new classes of anti-
hyperglycemic drugs have been made available for treat-
ment of T2D patients, including those with impaired renal
function, and some of these agents have shown car-
diorenal protection. In addition, the use of certain old
agents in patients with impaired eGFR has been recon-
sidered, thus further increasing the therapeutic options in
these individuals.
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